---
title: "Obefazimod (ABX464) in Ulcerative colitis: Natural history, survival, and mortality"
description: "Formulary evidence on Obefazimod (ABX464) in Ulcerative colitis: Natural history, survival, and mortality. Topics: Disease course: relapsing and remitting, with relapse in 70% to 80% by 10 years; Disease extent at diagnosis and proximal extension; Hospitalization and colectomy: contemporary US inception cohort; Colectomy: meta-analysis of population-based cohorts; 2 further topics. 6 evidence topics quoted from 7 sources."
canonical: "https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/product-information-and-disease-description/natural-history-survival-and-mortality"
published: "2026-11-18T10:42:55-05:00"
modified: "2026-11-18T10:42:55-05:00"
---

# Obefazimod (ABX464) in Ulcerative colitis: Natural history, survival, and mortality

<a id="heading-2.2.1.3"></a>

## 2.2.1.3 Natural History, Survival, and Mortality

<a id="topic-2.2.1.3-1"></a>

### Disease course: relapsing and remitting, with relapse in 70% to 80% by 10 years

> “The pattern of inflammatory disease activity is most often, relapsing and remitting, with symptoms of active disease alternating with periods of clinical quiescence (remission). Some patients with UC have persistent disease activity despite available medical therapy, and a small number of patients present with a rapid onset progressive and unresponsive type of fulminant colitis (4,5).”

Source: [Rubin et al. (2025)](https://journals.lww.com/ajg/fulltext/10.14309/ajg.0000000000003463)

> “Majority of patients have a mild-moderate course, most active at diagnosis and then in varying periods of remission or mild activity; about 10–15% patients experience an aggressive course, and the cumulative risk of relapse is 70–80% at 10 years. Almost 50% patients require UC-related hospitalization, and 5-year risk of re-hospitalization is ~50%.”
> “In the 10y follow-up study of the IBSEN cohort, four different profiles of disease activity were reported by patients: remission or mild severity after initial period of high activity (55%), chronic intermittent symptoms (37%), chronic continuous symptoms (6%) and increase activity after period of low activity (1%) (18).”

Source: [Fumery et al. (2018)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6658168/)

<a id="topic-2.2.1.3-2"></a>

### Disease extent at diagnosis and proximal extension

> “At diagnosis, the majority of patients had left-sided colitis (median 40.1%; IQR, 32.6–44.6); 30.5% (29.8–32.6) and 29.4% (25.3–34.7) were diagnosed with extensive colitis and proctitis, respectively (9–17).”
> “Overall rates of progression ranged from 12–30%, with cumulative 5-year risk of progression being approximately 13% (10,13,14).”

Source: [Fumery et al. (2018)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6658168/)

> “Up to 46% of patients with proctitis and 70% with left-sided colitis may develop extensive colitis on follow-up (95).”

Source: [Rubin et al. (2025)](https://journals.lww.com/ajg/fulltext/10.14309/ajg.0000000000003463)

<a id="topic-2.2.1.3-3"></a>

### Hospitalization and colectomy: contemporary US inception cohort

> “Cumulative 5y risk of all-cause and IBD-related hospitalization was 17% (95% CI, 16–19) and 11% (95% CI, 10–12), respectively (Table 2). Risk of all-cause and IBD-related hospitalization remained stable over era of IBD diagnosis (Figure 2D).”
> “Cumulative 1- and 5y risk of colectomy was 2.2% (95% CI, 1.8–2.7) and 5.7% (95% CI, 4.8–6.7), respectively (Table 2). Cumulative 5y risk of colectomy was lower in the more contemporary cohort (patients diagnosed in 2019–23 vs. 2007–12: 4.2% vs. 6.7%; aHR, 0.58 [95% CI, 0.38–0.89]) (Figure 2E).”

Source: [Ahuja et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13456955/)

> “Within 5 years of diagnosis, approximately 20% of patients with UC are hospitalized and approximately 7% undergo colectomy.”

Source: [Gros and Kaplan (2023)](https://pubmed.ncbi.nlm.nih.gov/37698559/)

<a id="topic-2.2.1.3-4"></a>

### Colectomy: meta-analysis of population-based cohorts

> “In patients with UC (26 studies), overall 1-, 5-, and 10-year risk of colectomy was 4.0% (95% CI,3.3–5.0), 8.8% (7.7–10.0) and 13.3% (11.3–15.5), respectively, with decline in risk over time (p<0.001). Corresponding contemporary risks were 2.8% (2.0–3.9), 7.0% (5.7–8.6) and 9.6% (6.3–14.2), respectively.”

Source: [Tsai et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8934200/)

<a id="topic-2.2.1.3-5"></a>

### Life expectancy: about 5 years shorter than people without ulcerative colitis

> “Life expectancy in people with UC is approximately 80.5 years for females and 76.7 years for males, which is approximately 5 years shorter than people without UC.”

Source: [Gros and Kaplan (2023)](https://pubmed.ncbi.nlm.nih.gov/37698559/)

<a id="topic-2.2.1.3-6"></a>

### Mortality: all-cause and cause-specific standardized mortality ratios

> “The all-cause mortality summary SMR for inception cohort and population cohort UC studies was 1.19 (95% confidence interval, 1.06–1.35).”
> “Mortality from colorectal cancer, pulmonary disease, and nonalcoholic liver disease was increased, whereas mortality from cardiovascular disease was decreased.”

Source: [Bewtra et al. (2013)](https://pmc.ncbi.nlm.nih.gov/articles/PMC3755276/)

> “UC has not been associated with an increased mortality, as compared to the general population, except in one cohort (23, 57–62).”
> “A meta-analysis of both administrative and inception population-based studies recently observed a pooled mortality rate of respectively 0.7% and 5.3% for elective and emergent surgery, respectively without significant decrease over time (39).”

Source: [Fumery et al. (2018)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6658168/)

> “UC causes significant morbidity but fortunately has a low incidence of mortality (6,7).”

Source: [Rubin et al. (2025)](https://journals.lww.com/ajg/fulltext/10.14309/ajg.0000000000003463)

Additional sources: [Jess et al. (2007)](https://pubmed.ncbi.nlm.nih.gov/17156150/)

## Related pages
- [Obefazimod (ABX464): Ulcerative colitis](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis) · [Markdown](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis.md)
- [Obefazimod (ABX464) in Ulcerative colitis: Terms and abbreviations](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/terms-and-abbreviations.md)
- [Obefazimod (ABX464): Ulcerative colitis](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/executive-summary) · [Markdown](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/executive-summary.md)
- [Obefazimod (ABX464) in Ulcerative colitis: Product information and disease description](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/product-information-and-disease-description.md)
- [Obefazimod (ABX464) in Ulcerative colitis: Clinical evidence](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/clinical-evidence.md)
- [Obefazimod (ABX464) in Ulcerative colitis: Economic information and modeling report](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/economics) · [Markdown](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/economics.md)
- [Obefazimod (ABX464) in Ulcerative colitis: References](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/references) · [Markdown](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/references.md)
